公开(公告)号：US08710036B2

公开(公告)日：2014-04-29

申请号：US13867674

申请日：2013-04-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Mark G. Currie ,  Steve Jones ,  Paul Grover ,  Chris H. Senanayake ,  Q. Kevin Fang

IPC: A61K31/58

CPC classification number: A61K45/06 ,  A61K31/137 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  Y10S514/87 ,  A61K2300/00

Abstract: Compositions containing β2 adrenergic agonists in combination with carbonates and carbamates of the formula. and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.

Abstract translation: 含有2种肾上腺素能激动剂与下式的碳酸酯和氨基甲酸酯组合的组合物。 并结合相关类固醇碳酸酯和氨基甲酸酯。 该组合物可用于治疗支气管痉挛，用于诱发支气管扩张和治疗鼻炎，哮喘和慢性阻塞性肺疾病（COPD）和炎性疾病，特别是通过吸入治疗。

公开(公告)号：US20140107175A1

公开(公告)日：2014-04-17

申请号：US14062626

申请日：2013-10-24

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming SHAO ,  Fengjiang Wang ,  Scott C. Malcolm ,  Michael C. Hewitt

IPC: C07D209/52

CPC classification number: C07D209/44 ,  A61K31/4035 ,  C07D209/08 ,  C07D209/52

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit re-uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Abstract translation: 本文提供的是双环化合物及其合成方法。 本文提供的化合物可用于治疗，预防和/或管理各种神经障碍。 本文提供的化合物抑制内源性单胺如多巴胺，5-羟色胺和去甲肾上腺素（例如，从突触裂缝）的再摄取并调节一种或多种单胺转运蛋白。 还提供了含有这些化合物的药物制剂。

公开(公告)号：US08501994B2

公开(公告)日：2013-08-06

申请号：US12196520

申请日：2008-08-22

Applicant: Craig R. Abolin ,  H. Scott Wilkinson ,  Paul McGlynn ,  William K. McVicar

Inventor： Craig R. Abolin ,  H. Scott Wilkinson ,  Paul McGlynn ,  William K. McVicar

IPC: C07C233/05 ,  A61K31/16

CPC classification number: C07C233/43 ,  A61K9/0075 ,  A61K9/008 ,  A61K31/167 ,  A61K31/4015 ,  A61K45/06 ,  C07B2200/13 ,  C07C231/18

Abstract: The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.

Abstract translation: 式（I）化合物是用作治疗与可逆性阻塞性气道疾病等相关的支气管收缩剂的支气管扩张剂的水稳定的长效β2-选择性肾上腺素受体激动剂。

公开(公告)号：US20130109677A1

公开(公告)日：2013-05-02

申请号：US13513176

申请日：2010-12-03

Applicant: Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

Inventor： Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

IPC: C07D495/04 ,  A61K31/55 ,  C07D495/20 ,  A61K31/435 ,  A61K31/381 ,  A61K45/06

CPC classification number: A61K31/381 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Abstract translation: 本文提供多环化合物，其合成方法，包含该化合物的药物组合物及其使用方法。 本文提供的化合物可用于治疗，预防和/或治疗各种神经障碍，包括但不限于精神病和精神分裂症。

公开(公告)号：US08389559B2

公开(公告)日：2013-03-05

申请号：US13148467

申请日：2010-02-05

Applicant: Liming Shao ,  Jianguo Ma

Inventor： Liming Shao ,  Jianguo Ma

IPC: A61K31/4025 ,  A61K31/40 ,  C07D207/06 ,  C07D405/04

CPC classification number: C07D207/06 ,  A61K31/40 ,  C07D207/08 ,  C07D207/12 ,  C07D405/04

Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

公开(公告)号：US08329950B2

公开(公告)日：2012-12-11

申请号：US13358155

申请日：2012-01-25

Applicant: Judy Caron ,  Thomas Wessel ,  Karim Lalji ,  Mark Varney ,  Roger P. Bakale ,  Surendra P. Singh ,  H. Scott Wilkinson ,  Xiping Su ,  Zhengxu Han ,  Stefan G. Koenig

Inventor： Judy Caron ,  Thomas Wessel ,  Karim Lalji ,  Mark Varney ,  Roger P. Bakale ,  Surendra P. Singh ,  H. Scott Wilkinson ,  Xiping Su ,  Zhengxu Han ,  Stefan G. Koenig

IPC: C07C209/62

CPC classification number: A61K31/4985 ,  A61K31/135 ,  C07C211/42 ,  C07C2602/10 ,  A61K2300/00

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract translation: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂当一起用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍时。 药物组合物的第一组分是镇静剂佐佐匹克。 药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基） 2,3,4-四氢-1-萘胺。 本发明还涉及治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。

公开(公告)号：US20120220598A1

公开(公告)日：2012-08-30

申请号：US13470046

申请日：2012-05-11

Applicant: Richard HSIA ,  H. Scott Wilkinson ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

Inventor： Richard HSIA ,  H. Scott Wilkinson ,  Tushar Misra ,  Kostas Saranteas ,  Patrick Mousaw

IPC: A61K31/4985 ,  A61P25/20

CPC classification number: C07D487/04

Abstract: A novel besylate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.

Abstract translation: （6-（5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4 -b]吡嗪）。

公开(公告)号：US08110706B2

公开(公告)日：2012-02-07

申请号：US12767043

申请日：2010-04-26

Applicant: Gerald J. Tanoury ,  Chris H. Senanayake ,  Donald W. Kessler

Inventor： Gerald J. Tanoury ,  Chris H. Senanayake ,  Donald W. Kessler

IPC: C07C231/20 ,  C07C233/03

CPC classification number: A61K31/205 ,  C07B2200/13 ,  C07C231/24 ,  C07C233/25 ,  C07C233/43

Abstract: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.

Abstract translation: 公开了制备R，R-福莫特醇L-酒石酸盐的高纯度盐的方法。 该方法通过重结晶新型多晶型物提供最热力学稳定的多晶型物。

公开(公告)号：US11767293B2

公开(公告)日：2023-09-26

申请号：US17748165

申请日：2022-05-19

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D207/09

CPC classification number: C07D207/09 ,  C07B2200/13

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US11738002B2

公开(公告)日：2023-08-29

申请号：US17228796

申请日：2021-04-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Carrie A. Bowen ,  Seth Cabot Hopkins ,  Colleen M. Synan

IPC: A61K31/381 ,  A61P25/18

CPC classification number: A61K31/381 ,  A61P25/18

Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.